The p53 protein, often dubbed the “guardian of the genome,” is pivotal in maintaining genomic stability, orchestrating DNA repair, cell cycle arrest, and apoptosis in response to damage. Cells deficient in p53 function are notorious for their enhanced susceptibility to genomic instability and increased mutation burden. By elucidating the relationship between heightened APOBEC3B expression and p53 loss, the study proposes a mechanistic framework explaining the acceleration of oncogenic mutagenesis in such contexts. APOBEC3B-induced mutations preferentially cluster, forming kataegic regions that promote genetic diversity within tumors, thereby fostering evolution and resistance to therapeutic interventions.

At the molecular level, APOBEC3B’s enzymatic activity converts cytosines to uracils on single-stranded DNA intermediates during DNA replication. The resultant lesions, if not correctly repaired, manifest as cytosine to thymine transitions or, occasionally, more complex mutation patterns. Intriguingly, the researchers observed that the kataegis-like mutation clusters arise particularly during episodes of replication stress—a condition exacerbated in p53-deficient cells due to aberrant cell cycle control and defective checkpoint activation. This intersection creates a vicious cycle, where APOBEC3B not only induces mutations but also contributes to replication fork instability, thereby amplifying genetic insults.

One of the pivotal discoveries in this correction highlights the potential therapeutic vulnerabilities emerging from this interplay. Cells harboring high APOBEC3B expression coupled with p53 defects demonstrate heightened dependency on replication stress response pathways. Inhibitors targeting ATR and CHK1—the central kinases mediating replication stress signaling—were found to be particularly effective in models mimicking this genetic landscape. This suggests a synthetic lethality approach, wherein the exploitation of replication stress exacerbated by APOBEC3B-induced DNA damage selectively kills p53-deficient cancer cells.

Moreover, the mutation signature delineated in this correction carries significant implications for cancer diagnostics and prognostics. The kataegis-like pattern serves as a molecular fingerprint for APOBEC3B activity and p53 loss, which can be harnessed to stratify patients based on mutation profiles. This could refine existing biomarker panels, enabling clinicians to identify tumors with elevated APOBEC3B activity that are more likely to respond to replication stress-pathway inhibitors. The clinical utility of such stratification is underscored by the challenges faced in treating p53-mutant cancers, which often exhibit poor prognosis and resistance to conventional therapies.

From an evolutionary standpoint, the role of APOBEC3B-induced kataegis in tumor heterogeneity cannot be overstated. The clustering of mutations facilitates rapid genetic diversification, enabling tumors to adapt under selective pressures such as hypoxia, immune surveillance, and chemotherapy. The replication stress exacerbated by APOBEC3B thus acts not only as a driver of mutation accumulation but also as a catalyst for tumor evolution. Understanding these dynamics is crucial for developing durable therapeutic strategies that anticipate and overcome resistance mechanisms.

Beyond therapeutics, this research correction refines our understanding of the fundamental biology of replication stress and DNA damage response in cancer cells. While replication stress is a hallmark of cancer, the study illustrates that its exacerbation by endogenous mutagenic enzymes like APOBEC3B is a critical contributor to oncogenesis in the absence of p53. This expands the canon of replication stress sources beyond exogenous insults and oncogene activation, positioning APOBEC3B as both a source and a modulator of genomic instability.

The correction also addresses the challenges of targeting APOBEC3B directly due to its physiological roles in innate immunity and viral defense. Instead, the identification of replication stress pathways as therapeutic targets offers a more tractable and selective approach to exploit the vulnerabilities conferred by APOBEC3B overexpression. This paradigm underscores the importance of understanding the contextual dependencies introduced by mutagenic stress rather than solely focusing on the mutagen itself.

Technological advancements in sequencing and bioinformatics were pivotal in characterizing these kataegic mutation signatures. Comprehensive analyses of whole-genome sequencing data from various tumor types revealed recurrent clustered mutations precisely associated with APOBEC3B activity. These clusters are often confined to specific genomic regions, highlighting the non-random nature of APOBEC3B mutagenesis and its preference for single-stranded DNA exposed during replication stress. This level of resolution empowers future studies aimed at mapping the mutational landscapes shaped by endogenous enzymatic processes.

Importantly, the study delineates the therapeutic index of replication stress inhibitors, emphasizing dose and timing considerations to maximize cancer cell kill while sparing normal cells. The synthetic lethality observed in p53-deficient, APOBEC3B-high contexts supports clinical trial designs incorporating biomarker-driven patient selection. Early-phase trials focusing on ATR and CHK1 inhibitors have shown promise, and this correction lends further mechanistic rationale to accelerate clinical translation.

This work further prompts a reconsideration of the functional consequences of kataegis beyond mutation accumulation. The clustered mutations may influence chromatin architecture, gene expression regulation, and DNA repair pathway choice, thereby reshaping the tumor microenvironment and response to therapies. The interplay between APOBEC3B activity, replication stress, and chromatin dynamics remains a fertile area for future research.

Additionally, the researchers highlight potential feedback loops wherein APOBEC3B expression is upregulated in response to replication stress, creating a self-reinforcing cycle of mutagenesis and genomic instability. Therapeutic interventions that disrupt these feedback mechanisms could provide durable suppression of tumor evolution and resistance.

Overall, this correction elaborates on a complex yet critical nexus involving APOBEC3B, p53 status, and replication stress, refining our understanding of cancer mutagenesis and treatment vulnerabilities. The findings underscore the need for integrating molecular insights into clinical strategies to effectively combat aggressive, p53-defective tumors.

As this field advances, the convergence of mutagenic enzymology, DNA damage response biology, and precision oncology heralds a new era in cancer therapeutics. Targeting the interplay between endogenous mutational processes and tumor suppressor loss represents a formidable yet promising frontier, one that could redefine outcomes for patients with refractory malignancies exhibiting these molecular hallmarks.

Subject of Research: Molecular mechanisms by which elevated APOBEC3B expression induces kataegis-like mutation signatures and replication stress in p53-deficient cancer cells, and the identification of related therapeutic vulnerabilities.

Article Title: Correction to: Elevated APOBEC3B expression drives a kataegic-like mutation signature and replication stress-related therapeutic vulnerabilities in p53-defective cells.

Article References:
Nikkilä, J., Kumar, R., Campbell, J. et al. Correction to: Elevated APOBEC3B expression drives a kataegic-like mutation signature and replication stress-related therapeutic vulnerabilities in p53-defective cells. Br J Cancer (2026). https://doi.org/10.1038/s41416-026-03352-x

Image Credits: AI Generated

In breast cancer, distinct subtypes display notable heterogeneity in ERS response. Estrogen receptor-positive (ER+) tumors often tolerate moderate ERS activation, which facilitates cellular adaptation. However, persistent ERS provokes apoptosis through intricate mitochondria-endoplasmic reticulum calcium signaling and reactive oxygen species (ROS) accumulation. Conversely, triple-negative breast cancers endure heightened baseline ERS, making them susceptible yet simultaneously adept at developing resistance via anti-apoptotic proteins such as FLIP. This dualistic nature exemplifies the balancing act cancer cells perform between survival and death, underscoring the challenge of exploiting ERS pathways therapeutically.

Within the complex tumor microenvironment, stressors like hypoxia, acidity, and nutrient scarcity act as relentless triggers for the unfolded protein response (UPR), perpetuating ERS signaling. ERS reciprocally remodels the microenvironment, simultaneously enhancing anti-tumor immunity by inducing immunogenic cell death (ICD) through modalities such as calreticulin exposition and HMGB1 release, while also promoting immunosuppression via mechanisms including PD-L1 glycosylation. Notably, ERS-mediated exosomal microRNAs, like miR-27a-3p, modulate macrophage immune checkpoint expression via molecular cascades, revealing sophisticated tumor immune escape strategies embedded within ERS signaling frameworks.

Colorectal cancer’s interplay between ERS and various cell death modalities underscores a nuanced regulatory landscape. The ferroptosis inducer RSL3 activates all UPR arms, with the PERK pathway dampening ferroptosis by modulating transcriptional regulation of critical cystine-glutamate antiporter components. This interplay suggests that modulating ERS pathways could overcome traditional apoptosis resistance, opening new therapeutic horizons. Moreover, dual induction of ferroptosis and ICD by agents like macrocarpal I enhances the efficacy of immune checkpoint blockade, highlighting the benefit of temporally calibrated ERS manipulation.

Hepatocellular carcinoma (HCC) demonstrates how ERS signaling pathways intertwine with diverse cell death forms to dictate tumor behavior and therapeutic outcome. Natural compounds, such as Icaritin and Fisetin, leverage ERS activation to induce mitochondrial dysfunction and calcium disruption, amplifying apoptotic pathways. Under therapeutic stress, ERS-induced autophagy serves as a protective shield against apoptosis, contributing to sorafenib resistance. Interventions that modulate this crosstalk, including melatonin’s inhibition of protective autophagy, reinstate drug sensitivity. Furthermore, ERS elements also govern metastatic potential by fostering anoikis resistance, indicating these pathways’ role extends beyond cell death into tumor dissemination.

Glioblastoma multiforme (GBM) epitomizes the challenges of therapy resistance linked to ERS/UPR dysregulation. Compounds such as sulforaphane induce ATF4–CHOP mediated apoptosis, whereas proteasome inhibitors, like marizomib, trigger caspase-dependent cell death independent of ROS or autophagy pathways. Intriguingly, remdesivir exhibits superior antitumor efficacy via PERK-orchestrated UPR, hinting at repurposed antiviral agents’ potential in oncology. The heterogenous ERS response in therapy-resistant GBM subtypes highlights the complexity of the tumor’s adaptive machinery and emphasizes the need for combination strategies targeting multiple ERS nodes.

Lung cancer progression and immune evasion are intimately linked with ERS-induced modulation of the tumor milieu. The oxidoreductase ERO1A shapes immunosuppressive environments by balancing IRE1α and PERK pathways and its inhibition potentiates PD-1 blockade responses. Other modulators like Derlin-3 drive macrophage polarization, reinforcing immune escape. Photodynamic therapies exploit ROS to instigate ERS and DNA damage, bolstering tumor immunogenicity. Furthermore, ERS-related gene signatures serve as prognostic indicators, with high-risk groups exhibiting blunted immune infiltration and attenuated treatment responses, illuminating the translational relevance of ERS biomarkers.

In pancreatic ductal adenocarcinoma (PDAC), ERS is a double-edged sword that propels tumor progression and resistance. Single-cell analyses have spotlighted tumor-associated neutrophil subsets with glycolytic profiles governed by ERS-associated transcription factors, fostering immunosuppression via chemokine secretion and checkpoint regulation. The molecular crosstalk where RUNX1 activates BiP/PERK/eIF2α signaling reinforces chemoresistance, which can be reversed pharmacologically. Nanotechnology-based delivery systems simultaneously targeting ERS pathways and immune checkpoints exemplify the frontiers of therapeutic innovation in this notoriously resistive cancer type.

Natural products across cancer types consistently emerge as potent ERS modulators to induce tumor cell death. Tocotrienols and oleandrin in breast cancer, curcumin and gambogenic acid in colorectal cancer, and secoemestrin C in PDAC exemplify the therapeutic potential harnessed from bioactive compounds targeting ERS-death axes. These agents engender ERS-mediated apoptosis through canonical pathways such as PERK-eIF2α-ATF4-CHOP or induce irreversible proteostasis collapse, thus overcoming conventional drug resistance mechanisms.

Therapeutic resistance often pivots on dynamic ERS responses where the equilibrium between death and survival signals is delicately tuned. For instance, sorafenib’s induction of protective autophagy via the PERK-ATF4-Beclin1 cascade in HCC demonstrates how a cytoprotective mechanism can complicate treatment outcomes. Agents that disrupt these survival cues restore apoptotic sensitivity, a principle echoed across tumor models. Similarly, in GBM, proteasomal activity modulates ERS and autophagy interplay, influencing temozolomide resistance, and targeting these pathways enhances therapeutic efficacy.

The tumor microenvironment reprogrammed by ERS influences metastatic progression and immune landscape remodeling. In HCC, ERS-adaptive proteins enhance anoikis resistance, promoting metastasis correlating with clinical metrics such as tumor size and stage. ERS-driven immunosuppressive signaling axes, like MIF/CD74+CXCR4, underscore how tumors manipulate local immunity to their advantage. Interventions that modulate ERS can shift this balance, restoring immune surveillance and dampening metastatic propensity.

Emerging therapies targeting the ERS machinery demonstrate profound potential in enhancing cancer treatment. Combinations such as PERK agonists with taxanes or proteasome inhibitors paired with ERS inhibitors unleash synergistic apoptotic responses. Novel targeted agents, including UBA1 and GRP78 inhibitors, induce irreversible UPR tipping cancer cells beyond their adaptive capacity. Nanoformulations augment delivery and efficacy of ERS modulators, underscoring the importance of technological advances in translating these molecular insights into clinical reality.

Metabolic reprogramming intimately intersects with ERS regulation, bridging cellular stress and tumor survival. Lung and pancreatic cancers exhibit metabolic alterations that integrate with ERS signaling to confer adaptive advantages. The PERK pathway, via modulators like BZW1 and PPARγ ligands, orchestrates glycolysis and ROS balance, influencing cell fate decisions under metabolic duress. Targeting these metabolic-ERS nodes disrupts tumor resilience, providing a multifaceted approach to combat resistant malignancies.

Within glioblastoma, the tumor’s subpopulation heterogeneity reveals distinct ERS dependencies that correlate with treatment sensitivity and recurrence. Strategies disrupting protein ubiquitination and folding, such as the UBA1 inhibitor TAK-243, combined with GRP78 antagonists, demonstrate remarkable potential in overcoming GBM robustness. Moreover, metabolic interventions harnessing ERS-mitochondrial crosstalk exploit vulnerabilities in glioma stem cells, emphasizing the crucial role of integrated stress responses in tumor eradication.

The immunogenic potential of ERS-induced cell death is increasingly recognized as a critical component in orchestrating effective antitumor immunity. Agents that trigger ICD, including several natural and synthetic compounds, not only kill cancer cells but also prime immune responses by exposing damage-associated molecular patterns. This dual function advocates for ERS-targeted therapies in combination with immunotherapies, aiming to dismantle immune evasion mechanisms entrenched within tumor microenvironments across cancer types.

The intricate nexus between ERS, programmed cell death, and the tumor microenvironment emerges as a fertile landscape for transformative cancer therapies. As the molecular choreography underlying ERS signaling pathways continues to unfold, it paves the way for innovative interventions that can finely tune this balance, circumvent resistance, and mobilize anti-tumor immunity. The future of oncology lies in decoding and manipulating this multifaceted axis to achieve durable clinical successes.

Subject of Research: Endoplasmic reticulum stress-mediated programmed cell death in the tumor microenvironment

Article Title: Endoplasmic reticulum stress-mediated programmed cell death in the tumor microenvironment

Article References:
Chai, H., Hu, Q., Yao, S. et al. Endoplasmic reticulum stress-mediated programmed cell death in the tumor microenvironment. Cell Death Discov. 11, 559 (2025). https://doi.org/10.1038/s41420-025-02862-6

Image Credits: AI Generated

DOI: 17 December 2025

A groundbreaking study published in BMC Cancer (2025) takes a deep dive into this pressing gap in bladder cancer research, unveiling a comprehensive prognostic signature by combining hypoxia and lactate metabolism-related genes. Employing a multifaceted bioinformatics approach coupled with rigorous experimental validation, researchers established a novel risk scoring system with remarkable ability to predict patient outcomes and shed light on bladder cancer heterogeneity. This work not only paves the way for more precise prognostication but also holds promise in guiding personalized therapeutic strategies for a notoriously difficult-to-treat cancer.

The investigators leveraged large-scale genomic data from The Cancer Genome Atlas (TCGA), applying unsupervised machine learning via the k-means clustering algorithm to stratify bladder cancer patients into distinct molecular subtypes. This initial classification revealed two predominant subgroups, each exhibiting unique molecular signatures reflective of differing hypoxia and lactate metabolism patterns. By focusing on genes associated specifically with hypoxia and lactate pathways, the team embarked on a rigorous gene selection process, featuring univariate Cox regression, random forest modeling, and stepwise multivariate Cox regression analyses to distill a robust prognostic model.

This analytical pipeline culminated in a 9-gene signature, a biomarker panel that performed with exceptional efficacy in predicting overall survival among bladder cancer patients. Those scoring high on this risk model uniformly displayed poorer prognoses, underscoring the clinical utility of this signature for risk stratification. Beyond prognostication, the model unveiled striking correlations between high-risk patients and an abundance of tumor-promoting immune cells—detected through sophisticated immune infiltration analyses—alongside an overall dampened immune functionality within the tumor microenvironment.

Such immune profiles have profound therapeutic implications. Intriguingly, patients with elevated risk scores also appeared less responsive to conventional immunotherapies and standard chemotherapeutic regimens, hinting at underlying resistance mechanisms driven by hypoxia and altered lactate metabolism. Furthermore, the study found that these high-risk tumors predominantly aligned with the basal molecular subtype of bladder cancer, a category characterized by aggressive clinical features and poor treatment outcomes. This finding reinforces the notion that metabolic and microenvironmental features are deeply intertwined with molecular taxonomy in bladder cancer.

Delving deeper into the biology of the genes constituting the signature, two candidates—GALK1 and TFRC—stood out. These genes were not only highly expressed in bladder tumors but experimentally confirmed to have functional roles in promoting tumor cell proliferation and migration, critical aspects fueling cancer progression. The researchers used single-cell RNA sequencing to map these genes’ expression across various cell subtypes within the tumor niche, shedding light on the cellular ecosystems that drive metabolic reprogramming and immune evasion.

The study’s experimental arm validated these insights, demonstrating that knocking down GALK1 and TFRC in bladder cancer cell lines impaired cellular growth and motility, thereby underscoring their oncogenic potential. This multifaceted evidence converges to position the hypoxia-lactate metabolism axis as a pivotal determinant of tumor aggressiveness and a promising target for therapeutic intervention. Moreover, the integration of bioinformatics with bench-side experiments exemplifies the power of translational research in pushing the boundaries of cancer biology.

Importantly, this newly established signature transcends beyond mere prognostication: it offers a predictive lens into treatment responses. The data suggest that the metabolic state of a tumor, as reflected by hypoxia and lactate dynamics, might serve as a biomarker to predict responsiveness to both immunotherapy and chemotherapy. Such insights could revolutionize clinical decision-making, guiding oncologists toward more tailored and effective treatment regimens that consider patients’ unique tumor biology.

Another critical dimension illuminated by this research is the heterogeneity of bladder cancer at the molecular and microenvironmental levels. The identification of discrete subsets within bladder cancer, differentiated by their metabolic and immune landscapes, challenges the one-size-fits-all approach pervasive in clinical practice. Instead, it beckons a new era of precision oncology that integrates metabolic phenotyping with traditional pathological and molecular classifications.

Bioinformatics played a foundational role in this research, harnessing powerful computational techniques to integrate vast datasets—transcriptomics, single-cell analyses, clinical outcomes—into actionable insights. The use of random forests and Cox regression models provided statistical rigor, enabling the distillation of complex gene expression patterns into clinically relevant tools. Meanwhile, single-cell transcriptomic profiling offered unprecedented resolution, uncovering cellular players and pathways at a granular level.

The implications of this study extend beyond bladder cancer. It exemplifies the broader shift in oncology toward understanding the metabolic underpinnings of tumor biology and their interactions with the immune system. Such insights could stimulate analogous research in other malignancies where hypoxia and lactate metabolism play a central role, potentially unlocking novel prognostic markers and treatment targets across cancer types.

In sum, this pioneering study presents a multi-gene hypoxia and lactate metabolism-related signature that effectively stratifies bladder cancer patients by prognostic risk, immune contexture, and therapeutic sensitivity. It highlights GALK1 and TFRC as critical drivers of tumor aggressiveness, providing new avenues for targeted interventions. The confluence of bioinformatics analyses and experimental validation sets a new benchmark for cancer biomarker discovery and translational research.

With bladder cancer continuing to claim numerous lives annually, the development of reliable prognostic tools and tailored therapies stands as an urgent priority. This innovative prognostic signature offers a timely and impactful resource, capable of refining patient management and improving outcomes. As the field advances, integrating metabolic profiling into clinical workflows may become standard practice, ushering in more personalized and effective cancer care.

Looking ahead, further exploration of the interactions between hypoxia, lactate metabolism, and the immune microenvironment could reveal additional therapeutic vulnerabilities. Coupling this signature with emerging therapies targeting metabolic pathways could open up new frontiers in bladder cancer treatment. Ultimately, studies like these underscore the transformative potential of systems biology and precision oncology in combating cancer’s heterogeneity and complexity.

Subject of Research: Bladder cancer prognosis and molecular subtyping via hypoxia and lactate metabolism gene integration.

Article Title: Elucidating a novel prognostic signature for bladder cancer by integrating hypoxia and lactate metabolism-related genes: comprehensive bioinformatics analyses and experimental evidence.

Article References:
Zhao, Y., Li, P., Shen, Z. et al. Elucidating a novel prognostic signature for bladder cancer by integrating hypoxia and lactate metabolism-related genes: comprehensive bioinformatics analyses and experimental evidence. BMC Cancer (2025). https://doi.org/10.1186/s12885-025-15010-1

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-15010-1

Cold atmospheric plasma has emerged as a promising anti-cancer tool due to its ability to generate reactive oxygen and nitrogen species that induce oxidative stress and cell death selectively in tumor cells. However, the efficacy of CAP treatment can be markedly influenced by the surrounding cellular milieu within the tumor, particularly immune cells such as macrophages. Macrophages are highly plastic immune cells capable of adopting distinct functional phenotypes in response to environmental cues. The M2 macrophage phenotype is generally associated with immunosuppressive, tissue remodeling, and tumor-promoting properties.

The new research reveals that M2 polarized macrophages confer a protective advantage to lung cancer cells exposed to CAP by alleviating endoplasmic reticulum (ER) stress, a critical driver of CAP-induced cytotoxicity. ER stress involves the accumulation of misfolded proteins within the ER lumen, triggering a cellular response known as the unfolded protein response (UPR). While prolonged ER stress leads to apoptosis, mitigating ER stress can enhance cancer cell survival under treatment-induced stress conditions.

Through a series of meticulous in vitro and in vivo experiments, the study demonstrates that conditioned media from M2 polarized macrophages significantly reduce markers of ER stress in lung cancer cells following CAP exposure. This reduction in ER stress corresponded with decreased apoptotic cell death and enhanced cell viability, highlighting a direct protective effect imparted by the macrophages. Conversely, M1 polarized macrophages—typically pro-inflammatory and anti-tumorigenic—did not exhibit this protective effect, underscoring the specificity of the M2 phenotype in promoting cancer cell resistance to CAP.

At the molecular level, the researchers identified key signaling pathways involved in this protective mechanism. The M2 macrophages secreted factors that modulated the PERK-eIF2α-ATF4 axis, a fundamental UPR pathway regulating ER stress responses. By attenuating the activation of PERK and downstream effectors, the macrophage-conditioned media effectively dampened the pro-apoptotic signals induced by CAP. This intricate crosstalk provides new insight into how tumor-associated macrophages can subvert therapeutic pressure by rewiring stress responses within cancer cells.

Importantly, these findings have significant implications for the clinical application of CAP in oncology. Lung cancers that possess a high infiltration of M2 polarized macrophages may exhibit intrinsic resistance to CAP therapy, necessitating combination strategies that target both cancer cells and their supportive immune microenvironment. Potential therapeutic approaches could involve reprogramming macrophage polarization from the tumor-promoting M2 state to the tumor-suppressing M1 phenotype or selectively inhibiting the macrophage-derived factors responsible for mitigating ER stress.

Furthermore, this study emphasizes the nuanced role of the tumor microenvironment in shaping responses to advanced therapies like CAP. While CAP offers a physical and chemical assault on cancer cells, the surrounding stromal and immune cells can actively counteract its effects, highlighting the complexity of tumor ecosystems. Comprehensive profiling of the tumor immune landscape may thus be crucial in predicting and improving patient responses to CAP and other oxidative stress-inducing treatments.

Beyond lung cancer, these insights could be extrapolated to other malignancies where macrophage polarization plays a pivotal role in therapy resistance. The idea that modifying macrophage phenotypes could potentiate CAP efficacy opens a new frontier for immunomodulatory interventions in cancer care. Researchers advocate for further studies to delineate the full spectrum of secreted factors and downstream signaling events mediating this protective effect.

The study utilized sophisticated cellular co-culture systems, flow cytometry, immunoblotting, and gene expression analyses to corroborate their findings, providing a robust experimental framework that marries immunology with plasma medicine. Additionally, animal models confirmed the in vivo relevance, as tumors with increased M2 macrophage content displayed reduced sensitivity to CAP, validating the clinical translatability of the results.

In summary, this pioneering research highlights the vital role of M2 polarized macrophages in orchestrating lung cancer cell survival during cold atmospheric plasma therapy by mitigating ER stress. It underscores the necessity of addressing the tumor microenvironment’s influence to overcome resistance mechanisms effectively. These revelations could inspire the development of combined modalities that integrate CAP with immunomodulatory agents, potentially transforming therapeutic paradigms for lung cancer patients.

As the field of plasma oncology advances, understanding such complex cellular interactions will be paramount to harnessing the full potential of CAP and other emerging treatments. This study serves as a compelling example of how dissecting tumor-immune interactions at the molecular level can unravel hidden mechanisms of resistance and inform innovative therapeutic strategies that ultimately improve patient outcomes.

Subject of Research: The protective role of M2 polarized macrophages in lung cancer cells against cold atmospheric plasma treatment by alleviating endoplasmic reticulum stress.

Article Title: M2 polarization of macrophage protects the lung cancer cells from cold atmospheric plasma via alleviating endoplasmic reticulum stress.

Article References:
Feng, Y., Peng, S., Zhao, L. et al. M2 polarization of macrophage protects the lung cancer cells from cold atmospheric plasma via alleviating endoplasmic reticulum stress. Cell Death Discov. 11, 487 (2025). https://doi.org/10.1038/s41420-025-02775-4

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41420-025-02775-4

Extracellular vesicles, particularly exosomes and microvesicles, carry an array of bioactive molecules, including proteins, lipids, and RNA, making them essential in intercellular communication. The significance of EVs in tumorigenesis has garnered attention for their involvement in various cancer types. They not only modulate the tumor microenvironment but also facilitate the acquisition of traits that promote cancer cell survival, proliferation, and metastasis. The mechanisms through which EVs operate present a fertile ground for research, particularly within the context of endometrial cancer, a malignancy that often proves resistant to conventional therapies.

Endometrial cancer cells can significantly alter the phenotype and function of TAMs through EVs. The relationship between these two cell types is crucial in shaping the tumor microenvironment. Through the transfer of specific RNA molecules and proteins within these vesicles, cancer cells can effectively ‘reprogram’ the macrophages, promoting a more supportive environment for tumor progression. This transformation is instrumental, as TAMs can be polarized into pro-tumorigenic or anti-tumorigenic phenotypes, ultimately influencing disease outcomes.

Research into the cargo of EVs derived from endometrial cancer cells reveals that they carry signaling molecules which may stimulate TAMs, leading to enhanced tumor growth. For instance, the presence of certain cytokines and growth factors within these EVs can push macrophages towards a phenotype that supports tumorigenesis, facilitating angiogenesis and immune evasion. Such findings underscore the importance of understanding the molecular signatures of EVs as potential biomarkers for cancer progression and prognosis.

Moreover, the therapeutic implications of targeting EVs in endometrial cancer are profound. By disrupting the communication pathways mediated by these vesicles, it may be possible to hinder the supportive role of TAMs, thereby enhancing the efficacy of existing therapies. As resistance to chemotherapy and targeted therapies remains a significant hurdle in the management of endometrial cancer, strategies that disrupt the EV-TAM communication axis could provide a novel approach to overcome this challenge.

The role of EVs in fostering a tumor-promoting environment is underscored by their involvement in the epithelial-mesenchymal transition (EMT), a process critical for cancer metastasis. EVs can facilitate the transfer of molecules that induce EMT in adjacent normal cells, converting them into cells that exhibit cancer stem cell-like properties. This cross-talk not only aids in the cancer cell’s mobility and invasiveness but also contributes to the makeup of the tumor microenvironment, further entrenching the tumor’s malignant behavior.

Additionally, the potential for using EVs as therapeutic vehicles is an exciting area of research. Due to their natural role in intercellular communication, EVs can be engineered to deliver therapeutic agents specifically to tumor-associated macrophages, providing a targeted approach to therapy. This novel method could enhance treatment outcomes while minimizing off-target effects, aligning with the growing trend toward personalized medicine in oncology.

In the context of immunotherapy, understanding the interplay between endometrial cancer cells, EVs, and TAMs could unveil new strategies for enhancing immune responses. EVs have been shown to carry immunosuppressive factors, which can dampen anti-tumor immunity. By deciphering the complex dynamics of EVs and their immune modulation, researchers hope to develop strategies that counteract these effects, reinvigorating the body’s immune system to combat cancer more effectively.

Moreover, expanding our knowledge of the molecular content of EVs can lead to the identification of novel biomarkers for early diagnosis and treatment monitoring in endometrial cancer. The presence of specific nucleic acids or proteins in the circulation has the potential to serve as non-invasive indicators of disease state, guiding treatment decision-making and improving patient prognostication.

While the promise of EV research is remarkable, several challenges remain. The complexity of EV biology requires advanced characterization techniques to elucidate their precise roles and mechanisms in cancer biology. Furthermore, ethical considerations and regulatory frameworks surrounding the use of biological materials must also be addressed as research advances towards clinical applications.

Endometrial cancer, largely affecting postmenopausal women, represents a significant health concern with rising incidence rates. The exploration of EVs in this context not only enhances our understanding of tumor biology but also paves the way for innovative therapeutic strategies. The dialogue between cancer cells and the immune system, as mediated by EVs, is a promising frontier that calls for further investigation to unlock the full potential of this unique mode of communication in cancer therapy.

As scientific inquiry advances, the potential of extracellular vesicles continues to unfold. From their role as messengers in cancer communication to their utility as vehicles for targeted therapy, EVs are at the forefront of cancer research, promising to bridge gaps in our understanding and treatment of endometrial cancer and beyond.

With ongoing studies and a deeper understanding of these cellular entities, the future of cancer treatment may well hinge on the successful manipulation of extracellular vesicle pathways. Shaping the conversation between tumor cells and the immune system is integral to formulating biologically-informed therapies that could revolutionize the landscape of cancer management.

The journey towards harnessing the power of extracellular vesicles is just beginning, but the insights gained thus far indicate a transformative potential in the fight against cancer, particularly in cases such as endometrial cancer where traditional therapies have fallen short of efficacy.

Subject of Research: The role of extracellular vesicles in the communication between endometrial cancer cells and tumor-associated macrophages.

Article Title: The role of extracellular vesicles in the communication between endometrial cancer cells and tumour-associated macrophages: a review.

Article References:

Li, F., Shi, W. The role of extracellular vesicles in the communication between endometrial cancer cells and tumour-associated macrophages: a review.
J Cancer Res Clin Oncol 151, 286 (2025). https://doi.org/10.1007/s00432-025-06318-3

Image Credits: AI Generated

DOI:

Keywords: Endometrial cancer, extracellular vesicles, tumor-associated macrophages, cancer communication, therapy resistance.

Lactylation, a post-translational modification characterized by the addition of a lactate moiety to target proteins, has garnered attention for its potential role in cellular signaling. This modification stems from the metabolic byproduct of glycolysis, linking cellular metabolism to gene expression and regulatory mechanisms. Shou and colleagues unveil how lactylation can influence miRNA activity, an area that has gone largely unexplored in the context of cancer therapy resistance. This connection suggests a complex interplay between metabolic pathways and the regulatory networks governing cancer progression and treatment responsiveness.

In their research, the authors first investigate the biochemical mechanisms underlying lactylation and its ability to modify specific miRNAs that have been implicated in cancer therapy. Through precise experimental manipulations, they demonstrate how lactate levels influence miRNA expression patterns, subsequently affecting the cellular responses to anti-cancer treatments. This finding highlights a crucial link between metabolic states and therapeutic efficacy, suggesting that cancer cells may adapt to treatment by altering their miRNA profiles through lactylation.

Furthermore, the study identifies specific miRNAs that are significantly regulated by lactylation. Among these are miRNAs that play pivotal roles in various tumorigenic processes, such as proliferation, apoptosis, and metastatic potential. By targeting these miRNAs, either through direct modification or utilizing novel therapeutic approaches, researchers can potentially enhance the effectiveness of existing therapies. This line of inquiry positions lactylation as a key player in the adaptive responses of cancer cells, rendering them more resilient against conventional treatments.

In their quest for understanding, Shou et al. also explore the broader implications of lactylation on the tumor microenvironment. Cancer cells exist in a highly dynamic and heterogeneous environment, where various factors including nutrient availability, pH, and metabolic state can profoundly influence their behavior. The authors propose that lactate signaling, facilitated by lactylation, could alter the interaction between cancer cells and their surrounding stroma. This alteration might contribute to an ecosystem that promotes therapy resistance, highlighting the need for a holistic approach in cancer treatment that considers both cancer cell metabolism and the microenvironment.

Moreover, the researchers underscore the potential of lactylation as a therapeutic target. By employing small molecules or biological agents that inhibit lactylation pathways, they have demonstrated the feasibility of manipulating miRNA expression levels in preclinical models. Such interventions could disrupt the ability of cancer cells to adapt to therapy, ultimately improving patient outcomes. This approach could represent a paradigm shift in how we understand and combat cancer resistance mechanisms, moving beyond traditional ideas that focus solely on the cancer cell itself.

The implications of this research extend to the realm of personalized medicine as well. Understanding how individual patients metabolically respond to treatments and how lactylation affects their unique miRNA profiles can inform the development of tailored treatment plans. This personalized approach not only holds promise for improving therapeutic efficacy but also for mitigating adverse effects associated with systemic treatments. By integrating lactylation and miRNA regulation into patient care strategies, oncologists could optimize therapy for each individual based on their metabolic state.

In considering the clinical translations of these findings, Shou et al. stress the importance of further investigations to validate their observations in clinical settings. Clinical trials that examine the relationship between lactylation status, miRNA profiles, and treatment responses could provide a wealth of data that shapes future therapeutic protocols. Such endeavors will necessitate multidisciplinary collaboration among oncologists, biochemists, and molecular biologists to foster a deeper understanding of this complex interplay.

As researchers continually unlock the intricate mechanisms of cancer therapy resistance, the role of lactylation emerges as an exciting new frontier. The study by Shou and colleagues serves as a pivotal entry point into this realm, setting the stage for future investigations that could transform the landscape of cancer treatment. By understanding and leveraging the lactylation-mediated regulation of miRNAs, researchers may uncover novel strategies to outsmart cancer and thwart its insidious ability to resist therapy.

While the path toward translating these findings into clinical practice remains fraught with challenges, the potential rewards are immense. As scientists unearth the connections between metabolism, epigenetics, and gene regulation, the hope is that these insights will culminate in more effective, less toxic cancer therapies. The journey of understanding lactylation’s influence on miRNA regulation, as delineated by Shou et al., represents a significant step forward in the ongoing battle against cancer, a battle that continuously demands innovative approaches and fresh perspectives.

The ongoing exploration of lactylation as a regulator in cancer therapy could lead not only to improved treatment regimens but also to a deeper understanding of cancer biology. As this research unfolds, the scientific community remains hopeful that these insights will not only advance our knowledge of cancer mechanisms but also empower clinicians to provide better, more effective care for patients facing this formidable disease.

In conclusion, the work of Shou et al. underscores the importance of exploring novel post-translational modifications like lactylation in the quest to unravel the complexities of cancer therapy resistance. As we stand on the cusp of new discoveries, the merging of biochemistry, molecular biology, and clinical research opens up a myriad of possibilities to combat one of humanity’s most daunting challenges. The journey is far from over, but with each step forward, we come closer to turning the tide against cancer.

Subject of Research: Lactylation-mediated miRNA regulation in cancer therapy resistance.

Article Title: Lactylation-mediated miRNA regulation in cancer therapy resistance.

Article References:

Shou, Y., Liu, R., Xiong, H. et al. Lactylation-mediated miRNA regulation in cancer therapy resistance.
J Transl Med 23, 941 (2025). https://doi.org/10.1186/s12967-025-06959-5

Image Credits: AI Generated

DOI: https://doi.org/10.1186/s12967-025-06959-5

Keywords: Lactylation, miRNA, cancer therapy resistance, post-translational modifications, cancer biology, metabolism, personalized medicine.

Over the past five years, the Quantitative Biology Fellows program has affirmed the critical importance of integrating robust computational skills with biological insight. These investigators are navigating the difficult terrain of cancer biology by deploying innovative theoretical frameworks alongside empirical evidence to decode intricate cellular mechanisms. They benefit from a unique funding structure, which provides $240,000 over three years and pairs postdoctoral scientists with dual mentors—an established computational scientist and a cancer biologist. This model fosters cross-disciplinary mentorship that is vital for the synthesis of quantitative and experimental approaches, enabling groundbreaking discoveries at the intersection of “wet” lab and “dry” lab research spheres.

One fellow, Dr. Simone Bruno at the Dana-Farber Cancer Institute, is focusing her work on triple-negative breast cancer (TNBC), one of the most aggressive and therapeutically challenging subtypes of breast cancer. Dr. Bruno’s research centers on the dynamics of chromatin—the structural arrangement of DNA and its regulatory proteins—and how directed alterations in this architecture influence cancer growth and resistance to therapies. Utilizing Bayesian inference to parameterize mathematical models that describe chromatin modification circuits, she intends to integrate these insights with pharmacokinetic and pharmacodynamic drug models. This composite computational framework aims to dissect the multifaceted mechanisms driving TNBC progression and resistance, potentially revealing novel intervention points to improve patient outcomes. Importantly, although TNBC serves as the model system, the methodologies developed here have broader applicability to diverse cancer types where chromatin remodeling is a pivotal factor.

At Memorial Sloan Kettering Cancer Center, Dr. Paul C. Klauser is pioneering computational protein design to overcome longstanding challenges in radiopharmaceutical development. Radiopharmaceuticals, which combine radioactive elements with targeting molecules, have transformed oncologic diagnostics and therapy but remain limited by the inefficiency of traditional chelators that bind radiometals. Dr. Klauser employs state-of-the-art diffusion models such as RFdiffusion to generate thousands of candidate protein scaffolds optimized for metal binding. These backbones are further refined using tools like ProteinMPNN and AlphaFold 3 to ensure structural stability and affinity for metals like copper, manganese, and lutetium. By engineering protein-based chelators capable of fusing with therapeutic antibodies, his computational methodology could vastly enhance the precision and efficacy of radiometal-based imaging and treatments, with a focus on HER2-positive gastric cancer yet far-reaching implications across cancers amenable to radiopharmaceutical interventions.

The adaptive immune response within tumor microenvironments is another frontier explored by Dr. Sohyeon Park at UCLA. Macrophages, specialized immune cells, exhibit “immune memory,” modifying their behavior based on previous antigen encounters, which can either inhibit or promote tumor progression. Despite recognition of this plasticity, the epigenetic and structural genomic basis of macrophage memory remains elusive. Dr. Park combines bulk Hi-C genomic data with machine learning-driven 3D chromosome reconstruction and deep learning image analysis to model how chromatin topology governs gene expression in macrophages. By quantifying spatial relationships between nuclear speckles and mRNA distribution, she seeks to mathematically characterize transcriptional regulation influenced by prior stimulation. This integrative computational and experimental approach aspires to unlock strategies for reprogramming macrophage memory, potentially tipping the balance toward enhanced anti-tumor immunity.

At the University of Texas Southwestern Medical Center, Dr. Ruoyu Wang addresses the enigmatic genomic “dark matter” of non-coding regions, which harbor regulatory elements vital to gene expression control and are frequently mutated in cancer. His innovative application of deep generative AI models to single-molecule regulatory genomics enables probabilistic exploration of chromatin state landscapes at DNA sequence resolution. By training these models on high-throughput genomic datasets, Dr. Wang’s framework can generate diverse hypothetical configurations of chromatin that reflect functional variability. This capability paves the way for high-fidelity annotation of the cancer regulatory genome, offering unprecedented granularity for discerning mutations that drive oncogenesis and identifying potential therapeutic targets within non-coding DNA.

The sophisticated temporal and spatial dynamics of gene regulation in cancer cells are the focus of Dr. Aaron Zweig’s work at the New York Genome Center. Employing stochastic differential equations to model gene expression trajectories over time, his computational pipeline incorporates provably identifiable linear and shallow neural networks optimized via adjoint differentiation techniques. Concurrently, spatial interactions among clustered transcriptomic data are analyzed through graph neural networks and self-attention mechanisms applied to latent gene embeddings derived from variational autoencoders integrating multi-modal RNA sequencing data. This approach uniquely captures both temporal variations and spatial heterogeneity in gene regulation, with particular relevance to acute myeloid leukemia (AML), where understanding transcriptional evolution could illuminate “precursor” cellular states and inform transplant immunotherapy strategies to minimize host tissue damage.

The Damon Runyon Cancer Research Foundation’s commitment to fostering such innovative quantitative research stems from its recognition that complex cancers demand equally complex and nuanced investigative tools. By supporting interdisciplinary collaborations that merge experimental oncology with computational modeling, Damon Runyon emphasizes the indispensable role quantitative biology plays in the era of personalized medicine. Through its intense selectivity—funding fewer than 10% of applicants—the Foundation ensures that only the most promising, visionary scientists gain support, promoting a culture of excellence that has historically propelled myriad breakthroughs, including multiple Nobel laureates.

The stories of these five fellows highlight how increasingly sophisticated computational methodologies are reshaping cancer research paradigms. From mathematical models simulating chromatin dynamics, deep learning–based structural genomics, protein engineering for radiotherapy, to complex neural network architectures capturing temporal-spatial gene regulation, these approaches exemplify the essential integration of quantitative rigor and biological insight. Their work stands as a testament to the transformative potential inherent in bridging computation and cancer biology—a synergy poised to deliver new therapeutic breakthroughs and precision interventions that could dramatically improve patient survival and quality of life.

As computational power and machine learning algorithms continue to evolve, the scientific community anticipates that such integrative frameworks will become standard tools within oncologic research. These fellows not only push the boundaries of knowledge but also exemplify the future of cancer research, where data-driven models and experimental validation go hand-in-hand to conquer one of medicine’s most formidable challenges. Their innovative projects reaffirm the belief that understanding cancer’s complexity at the molecular and cellular levels necessitates the convergence of diverse expertise, setting a new standard for collaborative science.

Subject of Research:

Cancer biology, computational biology, quantitative biology, chromatin dynamics, radiopharmaceutical design, immune cell epigenetics, regulatory genomics, machine learning, mathematical modeling.

Article Title:

Damon Runyon Names New Quantitative Biology Fellows Driving Computational Innovation in Cancer Research

News Publication Date:

Information not provided.

Web References:

http://damonrunyon.org

Keywords:

Cancer, Breast cancer, Quantitative analysis, Data analysis, Computational biology, Mathematical biology, Gene regulation, Mutation, Macrophages, Bioinformatics, Numerical analysis, Comparative analysis

For years, Galectin-1, a member of the lectin family known for its carbohydrate-binding properties, has been implicated in tumor progression due to its secretion by stromal fibroblasts, where it promotes immune evasion, angiogenesis, and matrix remodeling. However, until now, the intracellular functions of this molecule, particularly inside fibroblast nuclei, had remained largely unexplored. The recent findings published in the Proceedings of the National Academy of Sciences (PNAS) mark a paradigm shift by demonstrating that nuclear Galectin-1 exerts precise epigenetic control over gene expression programs that drive fibroblast activation, which in turn supports pancreatic tumor progression. This discovery elucidates a novel layer of tumor-stroma crosstalk that may open new therapeutic avenues.

Dr. Pilar Navarro, the coordinator of the Cancer Molecular Targets Research Group at the Hospital del Mar Research Institute and a leading figure in this investigation, explains that the stroma’s notorious role in pancreatic ductal adenocarcinoma (PDAC) aggressiveness hinges on the multifarious functions of fibroblasts. These cells not only secrete factors enhancing tumor cell survival and proliferation but also establish a physical barrier that impedes drug delivery. Importantly, fibroblasts’ secretion of Galectin-1 was known to contribute to these malignant attributes. “Our research reveals that Galectin-1 is not simply secreted into the tumor microenvironment, but it is also localized within the nuclei of stromal fibroblasts, where it functions as a critical regulator of gene expression,” Dr. Navarro remarks, highlighting the dual roles of the protein.

The team conducted comprehensive molecular analyses on pancreatic tumor tissue samples obtained from patients, confirming the nuclear presence of Galectin-1 in stromal fibroblasts in situ. Subsequently, cultured human fibroblast lines were utilized for mechanistic studies, revealing that nuclear Galectin-1 modulates specific gene networks through epigenetic mechanisms, such as histone modification or chromatin remodeling—processes that alter gene expression without changing the underlying DNA sequence. Notably, one of the most significant targets under the regulatory control of nuclear Galectin-1 is the oncogene KRAS, a canonical driver mutated in over 90 percent of PDAC cases and instrumental in promoting cancer cell proliferation and survival.

The regulation of KRAS expression inside fibroblasts is an unprecedented finding, suggesting that fibroblasts may adopt tumor-promoting phenotypes via intracellular signaling pathways converging on KRAS activation. Unlike the mutant version of KRAS in cancer cells, the fibroblast KRAS is wild-type but is upregulated by nuclear Galectin-1, thereby enhancing the supportive role fibroblasts play in tumor development. “This sheds light on a complex, reciprocal relationship wherein fibroblasts not only respond to tumor signals but also actively contribute to sustaining oncogenic programs,” elaborates Dr. Navarro.

These insights pave the way for therapeutic strategies targeting not only the extracellular effects of Galectin-1 but also its newly identified intracellular functions. Dr. Neus Martínez-Bosch, a researcher involved in the project, emphasizes this point, stating, “Previous attempts to inhibit Galectin-1 aimed at blocking the protein secreted by stromal cells. Our results suggest that to effectively disrupt fibroblast-tumor interactions, inhibitors must penetrate the fibroblast nucleus and inhibit Galectin-1’s gene regulatory activities.” Consequently, drug development efforts now face the challenge of identifying molecules capable of entering stromal fibroblasts and precisely modulating nuclear Galectin-1 activity.

To validate the therapeutic potential of targeting nuclear Galectin-1, scientists employed genetic and pharmacological methods to inhibit the protein and KRAS gene expression in cultured fibroblasts. The resultant effects were profound: fibroblast activation was attenuated, leading to a significant decrease in their capacity to sustain malignant behaviors in tumor cells. This evidence strongly supports the concept that disrupting the intracellular axis governed by Galectin-1 may impair the supportive stromal response essential for pancreatic cancer progression.

Dr. Judith Vinaixa, the study’s first author, underscores the breadth of gene expression regulation mediated by nuclear Galectin-1, noting the protein’s influence over multiple gene sets critical for controlling fibroblast behavior. Such multifactorial control mechanisms point to Galectin-1 as a master regulator within the tumor stroma, orchestrating complex epigenetic landscapes that facilitate cancer’s invasive and drug-resistant nature. The diverse roles of Galectin-1 suggest that its inhibition may yield pleiotropic antitumor effects beyond simply reducing fibroblast activation.

Complementing these findings, Dr. Gabriel Rabinovich, a co-investigator from IBYME (CONICET) and the CaixaResearch Institute, highlights the broader implications of Galectin-1 inhibition. Besides its fibroblast-nuclear functions, Galectin-1 contributes to angiogenesis and immune modulation within the tumor milieu, including resistance mechanisms against immunotherapies. Therefore, combined blockade of extracellular and intracellular Galectin-1 activities could synergistically impair tumor growth by both disrupting stromal support and enhancing immune-mediated tumor clearance. This multifaceted approach positions Galectin-1 as a highly promising target in the fight against pancreatic cancer, a disease urgently needing innovative therapeutic interventions.

The collaborative nature of this study, incorporating pathology experts from Hospital del Mar and cancer research specialists from CIBERONC, underscores the multidisciplinary effort required to unravel the complexities of the pancreatic tumor microenvironment. Their joint expertise facilitated the integration of histological evaluation with molecular biology and epigenetics, strengthening the validity and clinical relevance of the findings.

As the field moves forward, future research will inevitably focus on drug discovery tailored to inhibit nuclear Galectin-1, optimizing delivery systems to achieve efficient intracellular targeting in fibroblasts. Moreover, combination therapies that simultaneously target extracellular Galectin-1 and other tumor-promoting pathways could revolutionize treatment paradigms for pancreatic cancer. These innovative approaches stand to overcome one of the most formidable hurdles in oncology by dismantling the protective tumor stroma and restoring therapeutic efficacy.

Ultimately, this landmark study redefines our understanding of the pancreatic tumor microenvironment by spotlighting a novel nuclear function of Galectin-1 within stromal fibroblasts. The findings not only deepen the biological comprehension of stromal-tumor interactions but also open promising new pathways for the development of targeted therapies, giving hope to patients suffering from one of the deadliest cancers known today.

Subject of Research: Nuclear functions of Galectin-1 in pancreatic cancer-associated fibroblasts and its role in tumor progression

Article Title: Nuclear Galectin-1 promotes KRAS-dependent activation of pancreatic cancer stellate cells

News Publication Date: 15th April 2025

Web References:
https://doi.org/10.1073/pnas.2424051122

References:
Vinaixa J, Martínez-Bosch N, Gibert J, Manero-Rupérez N, Santofimia-Castaño P, Baudou FG, Vera RE, Pease DR, Iglesias M, Sen S, Wang X, Almada LL, Marks DL, Moreno M, Iovanna JL, Rabinovich GA, Fernandez-Zapico ME, Navarro P. Nuclear Galectin-1 promotes KRAS-dependent activation of pancreatic cancer stellate cells. Proc Natl Acad Sci U S A. 2025 Apr 8;122(14):e2424051122. doi: 10.1073/pnas.2424051122. Epub 2025 Apr 2. PMID: 40172967.

Keywords: Pancreatic cancer, tumor microenvironment, stroma, fibroblasts, Galectin-1, nuclear proteins, epigenetic regulation, KRAS gene, cancer-associated fibroblasts, tumor progression, drug resistance, immunotherapy resistance

Conventional methods for studying metabolic shifts in cancer cells tend to be resource-intensive and complex, often requiring specialized equipment that is not accessible to many researchers. The new technique aims to simplify this process, offering a more accessible alternative to researchers aiming to dissect the intricacies of tumor metabolism. Utilizing a standard fluorescence microscope, researchers can now visualize and quantify metabolic changes occurring at the single-cell level without the invasive and often costly procedures typically associated with such analyses.

The focus of the research team’s efforts was on head and neck squamous cell carcinoma (HNSCC), a malignancy recognized for its notorious resistance to various forms of radiation therapy. Through their innovative approach, the researchers were able to directly observe the metabolic alterations induced by radiation, particularly the upregulation of hypoxia-inducible factor 1 alpha (HIF-1α). This protein plays a crucial role in the cellular response to low oxygen conditions, which are prevalent in the microenvironment of solid tumors.

By deploying commercially available metabolic probes, the team measured the metabolic responses of different HNSCC cell lines to radiation treatment. The results emphasized a significant variation in HIF-1α expression levels, indicating that certain cell lines, such as rSCC-61, exhibited a marked increase in metabolic activity in response to radiation exposure. This finding suggests a strong metabolic shift towards radioresistance, highlighting how certain tumor cells can adapt and thrive in the face of therapeutic challenge.

One of the most compelling aspects of this study is the ability of researchers to reverse the metabolic adaptations associated with radioresistance. By strategically inhibiting HIF-1α within certain cancer cell lines, the researchers demonstrated that they could indeed enhance sensitivity to radiation treatment. This finding opens up avenues for therapeutic interventions that could potentially restore the efficacy of radiation in resistant cancers by targeting their metabolic adaptations.

This newly developed optical imaging technique holds the promise of becoming a game-changing tool in cancer research. It provides a unique and powerful methodology for the detailed examination of metabolic alterations on a single-cell basis. The use of readily available, low-cost microscopy and imaging software makes this technique not only more efficient but also democratizes the ability to study cancer metabolism across diverse laboratories.

The implications of this methodology extend beyond mere observation; it stands to inform the development of novel therapeutic strategies targeting the metabolic vulnerabilities of tumors. With more researchers gaining access to such tools, a broader range of studies can be conducted, potentially leading to breakthroughs that can alter the landscape of cancer treatments.

Senior author of the study, Caigang Zhu, emphasized the significance of this work in highlighting the practical challenges researchers face when employing expensive metabolic tooling for cancer studies. Zhu commented on the exciting nature of their results, which underscore the functional versatility of their optical approach to assess metabolic modifications in response to therapeutic stresses. The ability to perform such analyses with minimal expertise and using low-cost instruments represents a monumental shift in the accessibility of cancer research methodologies.

Moreover, this approach reflects a growing trend in scientific inquiry, where innovation does not solely derive from high-cost equipment but also from creative adaptations of existing technologies. By simplifying research methodologies, the potential exists for fostering a more expansive and inclusive research atmosphere, allowing a wider spectrum of scientists to contribute valuable insights into cancer biology.

As researchers delve deeper into the mechanistic understanding of metabolic reprogramming, the results gleaned from the use of this innovative technique are likely to yield critical insights into the fundamental processes that govern tumor resistance. Unraveling these complex relationships will be essential for the design of combination therapies that not only target the tumor cells directly but also the metabolic pathways they exploit for survival and proliferation.

Ultimately, this novel microscopy technique could set new standards in cancer metabolism research, enabling scientists to dissect the intricate interplay between metabolic adaptations and therapeutic interventions. As the field continues to evolve, the integration of such innovative methods promises to enhance our understanding and treatment of complex malignancies, steering the direction of future cancer research towards more effective and personalized therapeutic regimens.

The research findings, published in the journal Biophotonics Discovery, offer a compelling glimpse into the future of cancer diagnostics and therapeutic monitoring. The integration of fluorescence microscopy with sophisticated imaging software signifies a crucial step towards realizing a more nuanced understanding of tumor biology, especially the metabolic intricacies that underlie treatment resistance. This research could very well lay the groundwork for a new era of targeted cancer treatment that is responsive to the unique metabolic profiles of individual tumors.

All in all, as scientists continue to unravel the complexities of cancer metabolism, the techniques being developed could facilitate unprecedented advances in both basic and clinical research, potentially leading to improved outcomes for patients battling resistant forms of cancer.

Subject of Research: Metabolic Reprogramming in Cancer Cells
Article Title: Optical Imaging Technique for Studying Cancer Metabolism
News Publication Date: 28-Jan-2025
Web References: Biophotonics Discovery
References: J. Yan, C. F. L. Goncalves, et al. "Optical imaging provides flow-cytometry–like single-cell level analysis of HIF-1α-mediated metabolic changes in radioresistant head and neck squamous carcinoma cells," Biophotonics Discovery 2(1), 012902 (2025).
Image Credits: Credit: Yan et al., doi 10.1117/1.BIOS.2.1.012702.

Keywords: Cancer metabolism, Fluorescence microscopy, HIF-1α, Radioresistance, Metabolic reprogramming, Tumor biology, Imaging software, Single-cell analysis.